Intranasal oxytocin in the treatment of schizophrenia

Intranasal oxytocin in the treatment of schizophrenia - Intranasal oxytocin in the treatment of schizophrenia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014650

Enrollment

Registered

2014-08-01

Start date

2014-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Oxytocin was dosed at 24 IU twice a day for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The chronic schizphrenia patients whose body mass index was over 25.

Exclusion criteria

Exclusion criteria: Participants were excluded if they had a prior medical history of central nervous system disease or severe head injury, pregnancy or the possibility of pregnancy, or if they met the criteria for substance abuse or dependence.

Design outcomes

Primary

Measure	Time frame
The change of clinical symptoms calculated by the PANSS.	—

Secondary

Measure	Time frame
The change of social cognition and the body weight.	—

Countries

Japan

Contacts

Public ContactMiho Ota

National Center of Neurology and Psychiatry Department of Mental Disorder Research, National Institute of Neuroscience

ota@ncnp.go.p042-241-2712

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026